1118 related articles for article (PubMed ID: 12826528)
1. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
3. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
4. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
5. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
Castaman G; Federici AB; Rodeghiero F; Mannucci PM
Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
7. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
Auerswald G; Kreuz W
Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
[TBL] [Abstract][Full Text] [Related]
8. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
9. Von Willebrand's disease: clinical management.
Federici AB; Castaman G; Thompson A; Berntorp E
Haemophilia; 2006 Jul; 12 Suppl 3():152-8. PubMed ID: 16684011
[TBL] [Abstract][Full Text] [Related]
10. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
11. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III.
Houdijk WP; Sakariassen KS; Nievelstein PF; Sixma JJ
J Clin Invest; 1985 Feb; 75(2):531-40. PubMed ID: 3919060
[TBL] [Abstract][Full Text] [Related]
12. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
Berntorp E; Archey W; Auerswald G; Federici AB; Franchini M; Knaub S; Kreuz W; Lethagen S; Mannucci PM; Pollmann H; Scharrer I; Hoots K
Eur J Haematol Suppl; 2008 May; (70):3-35. PubMed ID: 18380871
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis in von Willebrand disease.
Berntorp E
Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
[TBL] [Abstract][Full Text] [Related]
15. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
Dunkley S; Baker RI; Pidcock M; Price J; Seldon M; Smith M; Street A; Maher D; Barrese G; Stone C; Lloyd J
Haemophilia; 2010 Jul; 16(4):615-24. PubMed ID: 20331755
[TBL] [Abstract][Full Text] [Related]
17. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
Escolar G; Carretero M; Magallón M; Quintana M; Arnau C; Castillo R; Aznar-Salatti J
Haematologica; 1998 Nov; 83(11):1009-14. PubMed ID: 9864923
[TBL] [Abstract][Full Text] [Related]
18. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
19. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
20. Management of inherited von Willebrand disease in 2006.
Federici AB
Semin Thromb Hemost; 2006 Sep; 32(6):616-20. PubMed ID: 16977571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
